JPWO2021183873A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021183873A5 JPWO2021183873A5 JP2022554769A JP2022554769A JPWO2021183873A5 JP WO2021183873 A5 JPWO2021183873 A5 JP WO2021183873A5 JP 2022554769 A JP2022554769 A JP 2022554769A JP 2022554769 A JP2022554769 A JP 2022554769A JP WO2021183873 A5 JPWO2021183873 A5 JP WO2021183873A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- thio
- pharmaceutical composition
- inhibitor
- immune checkpoint
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 claims 33
- 239000008194 pharmaceutical composition Substances 0.000 claims 33
- 206010028980 Neoplasm Diseases 0.000 claims 23
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 22
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 22
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 20
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 20
- 206010009944 Colon cancer Diseases 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 13
- 238000000034 method Methods 0.000 claims 12
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 8
- 201000007270 liver cancer Diseases 0.000 claims 8
- 208000014018 liver neoplasm Diseases 0.000 claims 8
- 201000005202 lung cancer Diseases 0.000 claims 8
- 208000020816 lung neoplasm Diseases 0.000 claims 8
- 206010005003 Bladder cancer Diseases 0.000 claims 7
- 208000003174 Brain Neoplasms Diseases 0.000 claims 7
- 206010006187 Breast cancer Diseases 0.000 claims 7
- 208000026310 Breast neoplasm Diseases 0.000 claims 7
- 206010008342 Cervix carcinoma Diseases 0.000 claims 7
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 7
- 206010025323 Lymphomas Diseases 0.000 claims 7
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 7
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 7
- 206010033128 Ovarian cancer Diseases 0.000 claims 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 7
- 239000012270 PD-1 inhibitor Substances 0.000 claims 7
- 239000012668 PD-1-inhibitor Substances 0.000 claims 7
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 7
- 206010060862 Prostate cancer Diseases 0.000 claims 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 7
- 208000000453 Skin Neoplasms Diseases 0.000 claims 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 7
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 7
- 206010057644 Testis cancer Diseases 0.000 claims 7
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 7
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 7
- 201000010881 cervical cancer Diseases 0.000 claims 7
- 208000029742 colonic neoplasm Diseases 0.000 claims 7
- 206010017758 gastric cancer Diseases 0.000 claims 7
- 201000010536 head and neck cancer Diseases 0.000 claims 7
- 208000014829 head and neck neoplasm Diseases 0.000 claims 7
- 208000032839 leukemia Diseases 0.000 claims 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 7
- 201000005443 oral cavity cancer Diseases 0.000 claims 7
- 201000002528 pancreatic cancer Diseases 0.000 claims 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 7
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 7
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 7
- 201000000849 skin cancer Diseases 0.000 claims 7
- 201000011549 stomach cancer Diseases 0.000 claims 7
- 201000003120 testicular cancer Diseases 0.000 claims 7
- 201000005112 urinary bladder cancer Diseases 0.000 claims 7
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 6
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 6
- 206010027406 Mesothelioma Diseases 0.000 claims 6
- 208000034578 Multiple myelomas Diseases 0.000 claims 6
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 6
- 206010029260 Neuroblastoma Diseases 0.000 claims 6
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 6
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 6
- 206010038389 Renal cancer Diseases 0.000 claims 6
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 6
- 201000009036 biliary tract cancer Diseases 0.000 claims 6
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 6
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 6
- 201000004101 esophageal cancer Diseases 0.000 claims 6
- 201000010982 kidney cancer Diseases 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 206010028537 myelofibrosis Diseases 0.000 claims 6
- 238000001959 radiotherapy Methods 0.000 claims 6
- 206010038038 rectal cancer Diseases 0.000 claims 6
- 201000001275 rectum cancer Diseases 0.000 claims 6
- 238000002560 therapeutic procedure Methods 0.000 claims 6
- 206010046766 uterine cancer Diseases 0.000 claims 6
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims 5
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 5
- 229940121420 cemiplimab Drugs 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229960003852 atezolizumab Drugs 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- -1 hormonal therapy Substances 0.000 claims 2
- 238000001794 hormone therapy Methods 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 2
- 229940121497 sintilimab Drugs 0.000 claims 2
- 229950007213 spartalizumab Drugs 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 229940125568 MGD013 Drugs 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 229940121418 budigalimab Drugs 0.000 claims 1
- 229950007712 camrelizumab Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229940011248 cosibelimab Drugs 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 229940121432 dostarlimab Drugs 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 230000008029 eradication Effects 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 229940018073 sasanlimab Drugs 0.000 claims 1
- 229950007123 tislelizumab Drugs 0.000 claims 1
- 229940121514 toripalimab Drugs 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 229940052007 zimberelimab Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062989041P | 2020-03-13 | 2020-03-13 | |
| US62/989,041 | 2020-03-13 | ||
| PCT/US2021/022090 WO2021183873A1 (en) | 2020-03-13 | 2021-03-12 | Sequential treatment of cancers using 6-thio-dg, checkpoint inhibitors and radiation therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023517671A JP2023517671A (ja) | 2023-04-26 |
| JPWO2021183873A5 true JPWO2021183873A5 (ko) | 2024-03-05 |
Family
ID=77671975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554769A Pending JP2023517671A (ja) | 2020-03-13 | 2021-03-12 | ６－チオ－ｄＧ、チェックポイント阻害剤および放射線療法を使用するがんの逐次処置 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210290652A1 (ko) |
| EP (1) | EP4117667A4 (ko) |
| JP (1) | JP2023517671A (ko) |
| KR (1) | KR20220154134A (ko) |
| CN (1) | CN115397428A (ko) |
| AU (1) | AU2021233023A1 (ko) |
| BR (1) | BR112022018238A2 (ko) |
| CA (1) | CA3170930A1 (ko) |
| IL (1) | IL296403A (ko) |
| MX (1) | MX2022011331A (ko) |
| WO (1) | WO2021183873A1 (ko) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103180463B (zh) * | 2010-10-22 | 2014-12-31 | 霍夫曼-拉罗奇有限公司 | 亲硫性固相以及包含硫代羰基核苷酸的寡核苷酸的缀合物 |
| BR112018000917A2 (pt) * | 2015-07-16 | 2018-09-11 | Bioxcel Therapeutics Inc | abordagem inovadora para o tratamento de câncer através da imunomodulação |
| US20180036331A1 (en) * | 2016-03-24 | 2018-02-08 | The Board Of Regents Of The University Of Texas System | Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds |
| EP3463370A4 (en) * | 2016-05-27 | 2020-04-08 | The Board of Regents of The University of Texas System | 6-THIO-2'-DESOXYGUANOSINE (6-THIO-DG) CAUSES TELOMERASE DEPENDENT TELEOMERS AND CELL DEATH IN THERAPY RESISTANT CANCER CELLS |
| WO2018049474A1 (en) * | 2016-09-16 | 2018-03-22 | Bionomics Limited | Antibody and checkpoint inhibitor combination therapy |
| EP3585812A1 (en) * | 2017-02-21 | 2020-01-01 | Regeneron Pharmaceuticals, Inc. | Anti-pd-1 antibodies for treatment of lung cancer |
| WO2019152574A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody |
| US20210023107A1 (en) * | 2018-03-22 | 2021-01-28 | The Board Of Regents Of The University Of Texas System | USE OF 6-THIO-dG TO TREAT THERAPY-RESISTANT TELOMERASEPOSITIVE PEDIATRIC BRAIN TUMORS |
-
2021
- 2021-03-12 JP JP2022554769A patent/JP2023517671A/ja active Pending
- 2021-03-12 CA CA3170930A patent/CA3170930A1/en active Pending
- 2021-03-12 MX MX2022011331A patent/MX2022011331A/es unknown
- 2021-03-12 CN CN202180028952.2A patent/CN115397428A/zh active Pending
- 2021-03-12 BR BR112022018238A patent/BR112022018238A2/pt unknown
- 2021-03-12 AU AU2021233023A patent/AU2021233023A1/en active Pending
- 2021-03-12 US US17/200,539 patent/US20210290652A1/en active Pending
- 2021-03-12 IL IL296403A patent/IL296403A/en unknown
- 2021-03-12 KR KR1020227033906A patent/KR20220154134A/ko active Search and Examination
- 2021-03-12 WO PCT/US2021/022090 patent/WO2021183873A1/en unknown
- 2021-03-12 EP EP21767125.4A patent/EP4117667A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007523862A5 (ko) | ||
| JP2021063120A5 (ko) | ||
| Nishimura | Rationale for chemoradiotherapy | |
| JP2008528486A5 (ko) | ||
| RU2010142390A (ru) | Комбинации конъюгата анти-her2-антитело-лекарственное средство и химиотерапевтических средств и способы применения | |
| CY1109607T1 (el) | Παραγωγο εποθιλονης για τη θεραπευτικη αντιμετωπιση του ηπατωματος και αλλων κακοηθων νοσων | |
| CN111132696A (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| US6281223B1 (en) | Radioenhanced camptothecin derivative cancer treatments | |
| JP2018511642A5 (ko) | ||
| Li et al. | Exploring hypoxic biology to improve radiotherapy outcomes | |
| CN112316149A (zh) | 一种治疗tp53突变的晚期难治性实体瘤的药物及应用 | |
| RU2010119922A (ru) | Усовершенствованное противоопухолевое лечение | |
| JPWO2021183873A5 (ko) | ||
| JPH1045589A (ja) | テモゾロミドによる改良されたガンの処置 | |
| JP2004537559A (ja) | Ｇｏｅ６９７６及びその関連化合物による癌治療 | |
| JP2006528696A (ja) | 抗癌剤の抗腫瘍活性を増強する方法 | |
| EP3960243A1 (en) | Pharmaceutical composition for preventing or treating treatment-resistant cancer | |
| JP7311177B2 (ja) | Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用 | |
| CN112741833A (zh) | 西达本胺及其衍生物的用途 | |
| JP2011513315A (ja) | 組合せ抗がん剤 | |
| RU2372901C2 (ru) | Способ комбинированного лечения местнораспространенного немелкоклеточного рака легкого | |
| Hussein et al. | ANTI-CANCER MEDICINS (CLASSIFICATION AND MECHANISMS OF ACTION) | |
| CN107137406B (zh) | 一种Hedgehog信号通路抑制剂在制备治疗EGFR过度表达的癌症的药物中的用途 | |
| RU2022125791A (ru) | Комбинации конъюгата анти-her2-антитело-лекарственное средство и химиотерапевтических средств и способы применения | |
| KR20230141704A (ko) | 방사선 및/또는 항암 치료 보조 요법으로 아데노신 디포스페이트 리보오스의 활용 |